Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Clinical Cancer Research|2025Cited by 7
Supplementary Table S2 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0
Supplementary Figure S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0
Supplementary Figure S4 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0
Supplementary Table S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0